IntelliCell BioSciences Announces That It Will Develop
Investigational Clinical Protocol Studies for the Treatment of ALS
With Dr. Manuel Trujillo
NEW YORK, NY--(Marketwired - Mar 24, 2014) - IntelliCell
BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a
regenerative medicine company utilizing adult autologous vascular
cells (SVCs) derived from the blood vessels found in adipose
tissue, announced today that it will be entering into a research
collaboration with Dr. Manuel Trujillo, Clinical Psychiatry NYU
Department of Psychiatry and Medical Director of the Amen Clinic,
to use its unique approach to the harvest and use of autologous
adipose derived stromal vascular fraction cells (SVFC) for clinical
studies of ALS (Lou Gehrig's Disease).
IntelliCell BioSciences and Dr. Trujillo are developing joint
investigational clinical study protocols with initial efforts
focusing on the assessment and treatment of patients with
ALS. The protocols will be conducted under an Investigational
New Drug Application ultimately in order to develop substantial
evidence of effectiveness that will meet the statutory new drug
approval standards as part of Intellicell's efforts to bring
scientific rigor to an area filled with anecdotal
evidence. Dr. Trujillo's sister, who is afflicted with ALS has
been treated as an individual patient with, among other therapies,
SVFCs, and showed improvement. The next step is controlled
clinical trials.
IntelliCell's Chief Executive Officer, Dr. Steven Victor,
remarked, "This is a tremendous honor for IntelliCell to work with
Dr. Trujillo in the field of ALS. This is a terrible disease
that afflicts many people, dramatically affecting their lives. We
believe that IntelliCell's Stromal Vascular Fraction Cells will
offer people with ALS a new and better way to have significant
improvement in their qualities of life. We at IntelliCell are
excited to have this opportunity to work with the distinguished
neuroscientist, Dr. Trujillo, and start investigational clinical
studies."
According to Dr. Trujillo, Chief Psychiatrist at the Amen
Clinics New York, "Dr. Victor's approach to stem cell treatments
using SVFCs is going to change the world for ALS patients. I am
excited to be part of this moment in scientific history and start
investigational clinical studies. I believe there is hope for
my ALS patients that never existed before."
About IntelliCell Biosciences IntelliCell is a pioneering
regenerative medicine company focused on the expanding regenerative
medical markets using adult autologous stromal vascular fraction
cells (SVFCs) derived from the blood vessels in the adult adipose
tissue. IntelliCell BioSciences has developed its own patented
technology and protocol to separate adult autologous vascular cells
from adipose tissue without the use of enzymes. IntelliCell will
also be seeking to develop technology-licensing agreements with
technology developers, universities, and international business
entities.
About ALS Amyotrophic lateral sclerosis (ALS), often referred to
as "Lou Gehrig's Disease," is a progressive neurodegenerative
disease that affects nerve cells in the brain and the spinal cord.
Motor neurons reach from the brain to the spinal cord and from the
spinal cord to the muscles throughout the body. The progressive
degeneration of the motor neurons in ALS eventually leads to their
death. When the motor neurons die, the ability of the brain to
initiate and control muscle movement is lost. With voluntary muscle
action progressively affected, patients in the later stages of the
disease may become totally paralyzed.
ALS is one of the most common neuromuscular diseases worldwide,
and people of all races and ethnic backgrounds are affected. One or
two out of 100,000 people develop ALS each year. Amyotrophic
lateral sclerosis affects approximately 30,000 Americans. ALS cases
are estimated at 1.2-4.0 per 100,000 individuals in Caucasian
populations with a lower rate in other ethnic populations. ALS most
commonly strikes people between 40 and 60 years of age, but younger
and older people can also develop the disease. Men are affected
slightly more often than women.
About Dr. Manuel Trujillo Manuel Trujillo, MD, chief
psychiatrist at Amen Clinics in New York, is a distinguished
clinician, academic administrator, and clinical services innovator
and researcher who dedicated his professional life to improving
clinical outcomes of psychiatric treatment.
Prior to joining Amen Clinics, Dr. Trujillo was Director of
Psychiatry at New York University -- Bellevue Hospital Center from
1991-2008, after holding senior clinical and administrative
positions at Columbia University College of Physicians and Surgeons
and other Schools of Medicine in New York City. During his term at
Bellevue, he developed numerous innovative clinical programs such
as culturally competent programs for Asians and Hispanics, and
directed the Department's extensive involvement in the
psychological aftermath of September 11, including outreach efforts
to victims, families, children, rescue workers, minorities and
other at risk populations.
In addition to his work at Amen Clinics, Dr. Trujillo is a
Clinical Professor of Psychiatry and Director, Program and
Fellowship in Public Psychiatry at New York University School of
Medicine. He is the recipient of many research and service grants
designed to improve treatment outcomes of severe and persistent
mental illness such as schizophrenia and bipolar disorders, as well
as create culturally competent treatment services and integrate
psychiatric and addiction services into primary care. His research
has contributed to the development of New York state policies that
provide optimum community care for seriously ill psychiatric
patients. He has written and presented extensively on Short-Term
Dynamic Psychotherapy and Cross-Cultural Psychiatry, among other
topics. In the last five years Dr. Trujillo has developed an
interest in bringing neuroimaging to the center of clinical
psychiatry and is actively collaborating with pioneers in this
field, such as Dr. Daniel Amen.
Dr. Trujillo received a Bachelor of Science degree and M.D. from
Seville University Medical School, Seville, Spain and completed his
residency in psychiatry at Albert Einstein College of Medicine, NY.
He received a fellowship from the Psychoanalytic Medicine Program,
Post Graduate Center for Mental Health in New York 1976, as well as
a Fellowship in Research Training in Psychiatry from the State
University of New York in 1978.
Forward-Looking Statements Certain statements set forth in this
press release constitute "forward-looking statements."
Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future
results, performance or achievements, and may contain the words
"estimate," "project," "intend," "forecast," "anticipate," "plan,"
"planning," "expect," "believe," "will likely," "will reach," "will
change," "will soon," "should," "could," "would," "may," "can" or
words or expressions of similar meaning. Such statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause the company's actual results and
financial position to differ materially from those included within
the forward-looking statements. Forward-looking statements involve
risks and uncertainties, including those relating to the Company's
ability to grow its business. Actual results may differ materially
from the results predicted and reported results should not be
considered as an indication of future performance. The potential
risks and uncertainties include, among others, the Company's
limited operating history, the limited financial resources,
domestic or global economic conditions, activities of competitors
and the presence of new or additional competition, and changes in
Federal or State laws. More information about the potential factors
that could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contact: IntelliCell BioSciences, Inc. Investor Relations Anna
Rhodes Email Contact (646) 576-8308